Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) has shared an announcement.
Sihuan Pharmaceutical Holdings Group Ltd. announced an update on the proposed spin-off and separate listing of its subsidiary, Xuanzhu Biopharm, on the Main Board of the Stock Exchange of Hong Kong Limited. The record date for determining the assured entitlement of qualifying shareholders to the SpinCo shares in the global offering is set for September 18, 2025. However, the proposed spin-off is subject to various conditions, including approval from the Stock Exchange and market conditions, and there is no assurance that it will proceed. Shareholders are advised to exercise caution, as the preferential offering will not proceed if the spin-off does not occur.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
More about Sihuan Pharmaceutical Holdings Group
Sihuan Pharmaceutical Holdings Group Ltd. is a company incorporated in Bermuda, primarily operating in the pharmaceutical industry. It focuses on the development and commercialization of pharmaceutical products, with a market focus that includes innovative drug development and biopharmaceuticals.
Average Trading Volume: 113,004,763
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.99B
For detailed information about 0460 stock, go to TipRanks’ Stock Analysis page.